ИНТЕРВЕНЦИОННАЯ КАРДИОЛОГИЯ – НОВОСТИ, СОБЫТИЯ И ТЕНДЕНЦИИ (по материалам on-line издания Cardiac Interventions Today)

В обзоре материалов, опубликованных в on-line издании «Cardiac Interventions Today» за 2015 год (Vol. 9), рассматриваются такие актуальные вопросы интервенционной кардиологии, как оказание помощи при остром инфаркте миокарда, осложненном кардиогенным шоком, и стратегия антитромбоцитарной терапии после чрескожного коронарного вмешательства.

инфаркт миокарда с подъемом сегмента ST, кардиогенный шок, коронарная реперфузия, остаточная реактивность тромбоцитов

1. O’Gara P. T., Kushner F. G., Ascheim D. D. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation / American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 2013; 61: e78–e140.

2. Menees D. S., Peterson E. D., Wang Y. et al. Door-toballoon time and mortality among patients undergoing primary PCI. N. Engl. J. Med. 2013; 369: 901–909.

3. Sleeper L. A., Ramanathan K., Picard M. H. et al. SHOCK Investigators. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J. Am. Coll. Cardiol. 2005; 46: 266–273.

4. Ezekowitz J. A., Kaul P., Bakal J. A. et al. Declining inhospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J. Am. Coll. Cardiol. 2009; 53: 13–20.

5. Braunwald E., Kloner R. A. Myocardial reperfusion: a double-edged sword? J. Clin. Invest. 1985; 76: 1713–1719.

6. Ong S. B., Samangouei P., Kalkhoran S. B., Hausenloy D. J. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J. Mol. Cell. Cardiol. 2015; 78C: 23–34.

7. Patel M. R., Smalling R. W., Thiele H. et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011; 306: 1329–1337.

8. O’Neill W. W., Schreiber T., Wohns D. H. et al. The current use of Impella 2,5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J. Interv. Cardiol. 2014; 27: 1–11.

9. Breet N. J., van Werkum J. W., Bouman H. J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010; 303: 754–762.

10. Price M. J., Berger P. B., Teirstein P. S. et al. GRAVITAS Investigators. Standard – vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305: 1097–1105.

11. Trenk D., Stone G. W., Gawaz M. et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug–eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J. Am. Coll .Cardiol. 2012; 59: 2159–2164.

12. Collet J. P., Cuisset T., Rangé G. et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 2012; 367: 2100–2109.

13. Gurbel P. A., Erlinge D., Ohman E. M. et al. TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012; 308: 1785–1794.